KAIMAI PAN

Counsel·Shanghai

KAIMAI PAN

Counsel·Shanghai

KAIMAI PAN

Counsel·Shanghai

PROFILE REPRESENTATIVE MATTERS AND CASES OTHER INFORMATION Further Reading

MR. PAN SPECIALIZES IN INTELLECTUAL PROPERTY-RELATED DISPUTE RESOLUTION, PARTICULARLY IN LITIGATION REGARDING PATENT LITIGATION, PATENT INVALIDATION, TRADE SECRET LITIGATION, AND TRADEMARK LITIGATION.

Education

Tsinghua University, School of Law, LL.M.

Tsinghua University, Chemistry and Biology, LL.B.

Professional Qualification

Admitted to practice in PRC

Admitted to practice before CNIPA

Work Language

English

Chinese Mandarin

Professional Background

Mr. Pan joined Fangda in 2018.

PROFILE

REPRESENTATIVE MATTERS AND CASES

  • Represented a leading Chinese mobile telecommunication technology company in litigation in China connected to global actions concerning global FRAND rate-setting of standard essential patents involving 5G, 4G, 3G and 2G standards
  • Represented a leading US wireless telecommunication technology company in litigation in China connected to global actions concerning licensing of standard essential patents involving 5G, 4G, 3G and 2G standards
  • Representing a Japanese manufacturer in two patent infringement cases and in two related patent invalidation cases against its Chinese competitor
  • Represented a US wireless telecommunication company in obtaining a favorable decision to maintain the validity of a standard essential patent challenged by a Chinese mobile telecommunication company
  • Represented a Chinese medical device company in obtaining a favorable decision to maintain the validity of a core patent challenged by its foreign competitor
  • Represented a Chinese biopharmaceutical company in successfully settling a trade secret misappropriation case brought against its Chinese competitor
  • Represented a German pharmaceutical company in winning several trade dress cases brought against its Chinese competitors
  • Represented a joint venture automobile company in winning a trademark infringement case
  • Represented a Chinese medicine manufacturing company in arbitration in an intellectual property contract dispute

OTHER INFORMATION

Further Reading

  • News

  • Articles